2024-10-29 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer goods company. The company has a long history of consistent growth and is known for its strong brand portfolio. 

**JNJ has significantly underperformed the S&P 500.**  As of the latest data, JNJ has a cumulative return of 34.87%, while the S&P 500 (VOO) has a return of 136.36%. This results in a **cumulative return difference of -101.49**, placing JNJ at the 3.58th percentile of historical performance relative to the S&P 500.

### 2. Recent Price Movement

* **Closing Price:** $161.6
* **5-day Moving Average:** $163.09
* **20-day Moving Average:** $162.18
* **60-day Moving Average:** $162.69

JNJ's current price is below its 5-day, 20-day, and 60-day moving averages, indicating a possible downward trend.

### 3. Technical Indicators

* **RSI:** 55.71 - JNJ is currently in the neutral territory (40-60) for RSI, suggesting no strong overbought or oversold signals.
* **PPO:** -0.03 - JNJ's PPO is slightly negative, indicating a slight downward momentum.
* **Delta_Previous_Relative_Divergence:** -2.23 (-) - This indicates a short-term downward trend in relative performance.
* **Expected Return:** 0.0% - Based on historical data and current conditions, JNJ is expected to have a 0% return compared to the S&P 500 over the long term (2+ years).

### 4. Recent Earnings and Outlook

| Date       | EPS  | Revenue          |
|------------|------|-------------------|
| 2024-10-23 | $1.12| $22.47B         |
| 2024-07-25 | $1.95| $22.45B         |
| 2024-05-01 | $1.35| $21.38B         |
| 2024-02-16 | $1.68| $21.39B         |
| 2023-10-27 | $10.32| $21.35B         |

JNJ's latest earnings were released on October 23rd, 2024. The company reported EPS of $1.12 and revenue of $22.47B. While earnings were lower than previous quarters, they still exceeded analyst expectations, indicating a positive trend for the company. 

### 5. Financial Trends Analysis

| Item               | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|--------------------|---------------|---------------|---------------|
| Revenue            | $22.47B         | $22.45B         | $21.38B         | 
| Gross Profit       | $15.51B         | $15.58B         | $14.87B         | 
| Gross Margin %     | 69.01%          | 69.40%          | 69.55%          | 
| Operating Income   | $5.28B          | $6.66B          | $6.27B          | 
| Operating Margin % | 23.49%          | 29.66%          | 29.34%          | 
| Net Income         | $2.69B          | $4.69B          | $3.25B          | 
| Net Margin %       | 11.99%          | 20.88%          | 15.22%          | 
| EPS                | $1.12           | $1.95           | $1.35           | 
| ROE %              | 3.84%           | 6.55%           | 4.65%           | 
| Total Assets       | $178.29B        | $181.09B        | $171.97B        | 
| Total Liabilities  | $108.13B        | $109.55B        | $101.95B        | 
| Total Equity       | $70.16B         | $71.54B         | $70.02B         | 
| Operating Cash Flow | $7.99B          | $5.63B          | $3.66B          | 
| Capital Expenditure | $-2.28B         | $-0.98B         | $-0.81B         | 

The company's financial performance shows a decline in net income and EPS in recent quarters. The Operating cash flow is also experiencing a downward trend. These factors may indicate a decrease in profitability and growth. However, JNJ's strong gross margin and consistent revenue growth suggest a stable business model. 

### 6. News and Recent Issues

Recent news about JNJ includes the company's successful launch of new products and advancements in its pharmaceutical pipeline. However, recent news articles also highlight concerns regarding the company's exposure to lawsuits related to talcum powder and other products. These lawsuits could impact JNJ's future financial performance and reputation.

Analysts remain cautious regarding the company's performance, expecting moderate growth in the near future. They believe the company's long-term prospects are still promising, but the legal and economic headwinds are likely to impact performance.

### 7. Overall Analysis

JNJ is a large and established company with a diverse product portfolio, but it faces various challenges including legal issues, competition, and a slowing market. The company's recent earnings are mixed, showing both positive and negative signs. 

**The overall performance of JNJ has been underwhelming compared to the S&P 500.** Its price is currently below its moving averages, and recent technical indicators suggest a possible downward trend.  While the company's fundamentals remain solid, investors should be aware of the potential risks and challenges that JNJ is currently facing.

**Investing in JNJ at this time requires a long-term perspective and a tolerance for potential risks.** Investors should closely monitor the company's financial performance, legal battles, and market trends to make informed decisions.

### 8. Report in English

This report provides an analysis of Johnson & Johnson (JNJ) stock.  We reviewed performance metrics, recent price trends, technical indicators, financial data, and recent news.

JNJ has underperformed the S&P 500 significantly, with a cumulative return difference of -101.49.  Its recent price movement suggests a possible downward trend. While the company's financial data shows some signs of weakness, JNJ's strong brand portfolio and diversified business model suggest resilience.

However, legal issues and competition pose challenges for the company.  Investors should be aware of these risks before making any investment decisions. 

Overall, JNJ is a large and established company, but its future performance may be impacted by legal headwinds and a slowing market.  Investors should carefully consider the company's strengths and weaknesses before making an investment.
